Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2013

01-11-2013 | Poster presentation

PB.50: Axillary lymph node ultrasound in breast cancer patients: what minimum threshold for diffuse cortical thickening predicts nodal involvement?

Authors: L Clarke, A Leaver, P Newton

Published in: Breast Cancer Research | Special Issue 1/2013

Login to get access

Excerpt

In our Trust we classify axillary ultrasound findings as LN1 to LN5, performing fine needle aspiration cytology (FNAC) on LN3 to LN5, where LN3 represents diffuse cortical thickening (DCT) of greater than 2 mm. The resulting FNAC triages patients to either sentinel lymph node biopsy or axillary node dissection. The aim is that patients will undergo only one axillary surgical procedure. There is variation in the literature and between breast units in the DCT threshold for performing FNA, and unnecessary FNAs should be avoided. Does the resulting cytology and surgical histology validate our 2 mm threshold; or can the threshold be safely increased to 2.3 mm or 3 mm as used by some centres? …
Metadata
Title
PB.50: Axillary lymph node ultrasound in breast cancer patients: what minimum threshold for diffuse cortical thickening predicts nodal involvement?
Authors
L Clarke
A Leaver
P Newton
Publication date
01-11-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3550

Other articles of this Special Issue 1/2013

Breast Cancer Research 1/2013 Go to the issue

Poster presentation

PB.44: Audit of interval cancers from family history breast screening

Poster presentation

PB.03: Evaluating the role of breast MRI at mid-cycle chemotherapy

Poster presentation

PB.43: Review of the determinants of poor screening uptake at City, Sandwell and Walsall Breast Screening Units and the steps taken to improve attendance

Oral presentation

4.5: Diagnosing breast cancer in a high-risk cohort

Poster presentation

PB.32: Does vacuum-assisted biopsy decrease the B3 rate in stereotactic biopsy of breast lesions?

Poster presentation

PB.36: Double reporting of patients discharged from the assessment clinic: the North Lancashire and South Cumbria experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits